Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Change in Account Payables (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Change in Account Payables for 7 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • Quarterly Change in Account Payables rose 317.09% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.0 million through Dec 2025, up 234.26% year-over-year, with the annual reading at $6.0 million for FY2025, 234.26% up from the prior year.
  • Change in Account Payables for Q4 2025 was $1.2 million at Beam Therapeutics, up from -$1.6 million in the prior quarter.
  • The five-year high for Change in Account Payables was $3.8 million in Q1 2025, with the low at -$3.0 million in Q3 2023.
  • Average Change in Account Payables over 5 years is $173000.0, with a median of -$64500.0 recorded in 2022.
  • The sharpest move saw Change in Account Payables surged 1012.89% in 2021, then crashed 2584.31% in 2023.
  • Over 5 years, Change in Account Payables stood at $2.2 million in 2021, then surged by 34.32% to $2.9 million in 2022, then crashed by 160.97% to -$1.8 million in 2023, then skyrocketed by 68.89% to -$550000.0 in 2024, then skyrocketed by 317.09% to $1.2 million in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at $1.2 million, -$1.6 million, and $2.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.